Drug Trial Radar · NCT03440736
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
781
Actual
Start
Feb 28, 2018
Primary completion
Nov 30, 2021
Study completion Jun 3, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could primarily improve skin symptoms and secondly cardiometabolic status more than Secukinumab alone in psoriasis patients with concomitant metabolic syndrome by targeting the shared pathophysiology behind both diseases, which is systemic inflammation.
Conditions
- Psoriasis
- Metabolic Syndrome
Interventions
SecukinumabDrug
Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
Life-style interventionBehavioral
A structured program to guide weight loss and increased physical activity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Achieving Psoriasis Area and Severity Index (PASI) Score of 90 at Week 28Time frame: Baseline, Week 28
Locations
75 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Andernach, Germany
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Bad Soden, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bielefeld, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Braunschweig, Germany
Novartis Investigative Site
Darmstadt, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Falkensee, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Friedrichshafen, Germany
Novartis Investigative Site
Gera, Germany
Novartis Investigative Site
Greifswald, Germany
Novartis Investigative Site
Hagen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hanau, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Ibbenbueren, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Löhne, Germany
Novartis Investigative Site
Lüdenscheid, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Memmingen, Germany
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.